Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Microba Life Sciences Ltd ABN: 82 617 096 652 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Pasquale Rombola Date of last notice 15 August 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest 1. Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. 1. Rombola Family Pty Ltd <Rombola Family A/C>. Pasquale Rombola is the sole director and sole shareholder of Rombola Family Pty Ltd and a beneficiary of the Rombola Family Trust 2. Rombola Superannuation Pty Ltd <Rombola Super Fund A/C>. Pasquale Rombola is a director and a shareholder of Rombola Superannuation Pty Ltd and a beneficiary of the Rombola Super Fund. Date of change 29 July 2026 No. of securities held prior to change 1. 6,200,000 Ordinary Shares & 250,000 Options exercisable at $0.14, expiring 13 August 2027. 2. 370,000 Ordinary Shares & 50,000 Options exercisable at $0.14, expiring 13 August 2027. Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Class Ordinary Shares & Options Number acquired 1. 1,000,000 Ordinary Shares and 1,000,000 Options exercisable at $0.0625, expiring 29 July 2029. 2. 250,000 Ordinary Shares and 250,000 Options exercisable at $0.0625, expiring 29 July 2029. Number disposed Nil Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation $62,500 in aggregate, being $0.05 per Ordinary Share, comprising $50,000 (1) and $12,500 (2). The Options were issued for nil cash consideration on the basis of one free attaching Option for every one Ordinary Share subscribed for. No. of securities held after change 1. 7,200,000 Ordinary Shares, 250,000 Options exercisable at $0.14, expiring 13 August 2027, and 1,000,000 Options exercisable at $0.0625, expiring 29 July 2029. 2. 620,000 Ordinary Shares, 50,000 Options exercisable at $0.14, expiring 13 August 2027, and 250,000 Options exercisable at $0.0625, expiring 29 July 2029. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Participation in Tranche 2 of the Placement announced to the ASX on 12 June 2026, approved by Shareholders under ASX Listing Rule 10.11 at the General Meeting held on 24 July 2026 (Resolutions 4(a) and 4(b)). Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A